{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T08:02:46Z","timestamp":1769500966091,"version":"3.49.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.msard.2017.12.004","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T13:55:14Z","timestamp":1513173314000},"page":"1-2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Refractory epilepsy following natalizumab associated PML"],"prefix":"10.1016","volume":"20","author":[{"given":"Tarig Mohammed","family":"Abkur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugh","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2017.12.004_bib1","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2017.12.004_bib2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1212\/01.wnl.0000194227.16696.11","article-title":"Seizures and their outcome in progressive multifocal leukoencephalopathy","volume":"66","author":"Lima","year":"2006","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2017.12.004_bib3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1148\/radiology.173.2.2798883","article-title":"Progressive multifocal leukoencephalopathy in patients with AIDS: appearance on MR images","volume":"173","author":"Mark","year":"1989","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.msard.2017.12.004_bib4","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00415-012-6759-0","article-title":"Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab","volume":"260","author":"Mc Govern","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2017.12.004_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","article-title":"Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis","volume":"15","author":"Scolding","year":"2015","journal-title":"Pract. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034817303449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034817303449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:42:28Z","timestamp":1761900148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034817303449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":5,"alternative-id":["S2211034817303449"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2017.12.004","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refractory epilepsy following natalizumab associated PML","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2017.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}